US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.44

+0.150011.63%

Post-market: 1.440.00000.00%19:30 EDT

Volume:570.61K

Turnover:812.10K

Market Cap:9.59M

PE:-0.30

High:1.49

Open:1.35

Low:1.34

Close:1.29

52wk High:12.80

52wk Low:0.6201

Shares:6.66M

Float Shares:5.84M

Volume Ratio:2.02

T/O Rate:9.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.7656

EPS(LYR):-8.3501

ROE:-660.08%

ROA:-95.77%

PB:2.07

PE(LYR):-0.17

Loading ...

Overview Company News Filings

FibroBiologics shareholders approve 2026 equity incentive plan at annual meeting

Fibrobiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

THOMSON REUTERS

FibroBiologics gets USPTO notice of allowance for topical fibroblast spheroid wound-healing patent application

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

FibroBiologics doses first patients in CYWC628 clinical trial

FibroBiologics doses first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers

Fibrobiologics Inc: Continues to Advance Manufacturing of Cywc628 to Support Ongoing Trial Activity

THOMSON REUTERS

Fibrobiologics - to Ship Second Gmp Run of Cywc628 to Australia Week of June 15, 2026

THOMSON REUTERS

Fibrobiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of Cywc628 for the Treatment of Diabetic Foot Ulcers

THOMSON REUTERS

Fibrobiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating Cywc628 for the Treatment of Diabetic Foot Ulcers

THOMSON REUTERS

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics presents CYPS317 preclinical psoriasis data showing durable immunomodulation

Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics

THOMSON REUTERS

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

FibroBiologics expands fibroblast-based platform to target Hantavirus

Fibrobiologics Shares Down 13%

THOMSON REUTERS

Fibrobiologics Shares NOW Down 15% Premarket at 99 Cents

THOMSON REUTERS

FibroBiologics expands fibroblast platform to target Hantavirus pulmonary syndrome

Fibrobiologics Advancing Development of a Fibroblast Treatment for Hantavirus

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/FBLG/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":1.44,"timestamp":1787342400000,"preClose":1.29,"halted":0,"volume":570614,"hourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.44,"latestTime":"19:30 EDT","volume":2511,"amount":3613.844,"timestamp":1787355006957,"change":0,"changeRate":0,"amplitude":0.006944},"delay":0,"changeRate":0.11627906976744179,"floatShares":5843116,"shares":6658193,"eps":-4.765638,"marketStatus":"Market Closed","change":0.15,"latestTime":"08-21 16:00:00 EDT","open":1.35,"high":1.4888,"low":1.34,"amount":812103.4368172,"amplitude":0.115349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.765638,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":1.29,"preHourTrading":{"tag":"盘前","latestPrice":1.35,"preClose":1.29,"latestTime":"09:29 EDT","volume":11237,"amount":15572.155941,"timestamp":1787318999999,"change":0.06,"changeRate":0.046512,"amplitude":0.062016},"postHourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.44,"latestTime":"19:30 EDT","volume":2511,"amount":3613.844,"timestamp":1787355006957,"change":0,"changeRate":0,"amplitude":0.006944},"volumeRatio":2.023366365359968},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":5843116,"roa":"-95.77%","roe":"-660.08%","lyrEps":-8.3501,"volumeRatio":2.023366365359968,"shares":6658193,"dividePrice":0,"high":1.4888,"amplitude":0.115349,"preClose":1.29,"low":1.34,"week52Low":0.62005,"pbRate":"2.07","week52High":12.8,"institutionHeld":0,"latestPrice":1.44,"eps":-4.765638,"divideRate":0,"volume":570614,"delay":0,"ttmEps":-4.765638,"open":1.35,"prevYearClose":4.498,"prevWeekClose":1.06,"prevMonthClose":0.7,"prevQuarterClose":0.9477,"fiveDayClose":1.06,"twentyDayClose":0.712,"sixtyDayClose":1.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-31","symbol":"FBLG","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785470400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-04-30","symbol":"FBLG","fiscalQuarterEnding":"2026/03","expectedEps":-1.26,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":-1.33},{"market":"US","date":"2026-03-30","symbol":"FBLG","defaultRemindTime":1774877400000,"type":"split","dateTimestamp":1774843200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2026-02-24","symbol":"FBLG","fiscalQuarterEnding":"2025/12","expectedEps":-0.09,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771909200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2026-08-21","current":-0.302163,"percent":0.841935,"low":-68.573467,"twenty":-5.885273,"median":-2.907657,"eighty":-0.890492,"high":-0.181252,"avg":-5.889048,"sd":9.591455,"marketCap":8589068},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805},{"date":"2025-11-21","current":-0.902797,"twenty":-13.070223,"median":-4.004863,"eighty":-2.130838,"marketCap":16702642},{"date":"2025-11-28","current":-0.907742,"twenty":-12.733301,"median":-3.95212,"eighty":-2.105769,"marketCap":16794130},{"date":"2025-12-05","current":-0.861361,"twenty":-11.417566,"median":-3.918378,"eighty":-2.038689,"marketCap":15936036},{"date":"2025-12-12","current":-1.151904,"twenty":-11.10969,"median":-3.880347,"eighty":-1.962831,"marketCap":21311383},{"date":"2025-12-19","current":-0.864342,"twenty":-10.563644,"median":-3.855551,"eighty":-1.925449,"marketCap":15991199},{"date":"2025-12-26","current":-0.781519,"twenty":-10.366139,"median":-3.817676,"eighty":-1.905048,"marketCap":14458888},{"date":"2026-01-02","current":-0.80862,"twenty":-10.104734,"median":-3.784683,"eighty":-1.867667,"marketCap":14960285},{"date":"2026-01-09","current":-1.186504,"twenty":-9.756195,"median":-3.726488,"eighty":-1.863485,"marketCap":21951508},{"date":"2026-01-16","current":-1.21347,"twenty":-9.439605,"median":-3.689721,"eighty":-1.817994,"marketCap":22450406},{"date":"2026-01-23","current":-1.222459,"twenty":-8.832939,"median":-3.685286,"eighty":-1.804182,"marketCap":22616705},{"date":"2026-01-30","current":-1.226773,"twenty":-8.114091,"median":-3.670176,"eighty":-1.745069,"marketCap":22696529},{"date":"2026-02-06","current":-0.81653,"twenty":-7.942868,"median":-3.64061,"eighty":-1.71998,"marketCap":15106628},{"date":"2026-02-13","current":-0.884485,"twenty":-7.806733,"median":-3.5628,"eighty":-1.705851,"marketCap":16363851},{"date":"2026-02-20","current":-0.903181,"twenty":-7.769521,"median":-3.544415,"eighty":-1.692292,"marketCap":16709754},{"date":"2026-02-27","current":-1.025558,"twenty":-7.720912,"median":-3.492982,"eighty":-1.665999,"marketCap":19122546},{"date":"2026-03-06","current":-1.519667,"twenty":-7.689204,"median":-3.463009,"eighty":-1.553538,"marketCap":28335707},{"date":"2026-03-13","current":-1.232917,"twenty":-7.578225,"median":-3.43637,"eighty":-1.519667,"marketCap":22988964},{"date":"2026-03-20","current":-0.927678,"twenty":-7.514809,"median":-3.414459,"eighty":-1.43094,"marketCap":17297489},{"date":"2026-03-27","current":-0.797535,"twenty":-7.246713,"median":-3.39431,"eighty":-1.385333,"marketCap":14870838},{"date":"2026-04-02","current":-0.241073,"twenty":-7.177005,"median":-3.378022,"eighty":-1.359957,"marketCap":4495048},{"date":"2026-04-10","current":-0.336129,"twenty":-7.067291,"median":-3.359084,"eighty":-1.328997,"marketCap":6267453},{"date":"2026-04-17","current":-0.370229,"twenty":-6.822821,"median":-3.321721,"eighty":-1.299599,"marketCap":6903282},{"date":"2026-04-24","current":-0.367793,"twenty":-6.742593,"median":-3.30892,"eighty":-1.267223,"marketCap":6857865},{"date":"2026-05-01","current":-0.368753,"twenty":-6.533559,"median":-3.275657,"eighty":-1.232416,"marketCap":6875767},{"date":"2026-05-08","current":-0.345774,"twenty":-6.468368,"median":-3.258236,"eighty":-1.221308,"marketCap":6459054},{"date":"2026-05-15","current":-0.312154,"twenty":-6.322318,"median":-3.235952,"eighty":-1.201893,"marketCap":5831040},{"date":"2026-05-22","current":-0.303483,"twenty":-6.255297,"median":-3.19076,"eighty":-1.171044,"marketCap":5669067},{"date":"2026-05-29","current":-0.326606,"twenty":-6.214848,"median":-3.171598,"eighty":-1.119059,"marketCap":6100996},{"date":"2026-06-05","current":-0.309264,"twenty":-6.16305,"median":-3.157497,"eighty":-1.023143,"marketCap":5777049},{"date":"2026-06-12","current":-0.278626,"twenty":-6.143005,"median":-3.135055,"eighty":-0.995266,"marketCap":5204743},{"date":"2026-06-18","current":-0.231225,"twenty":-6.14132,"median":-3.119296,"eighty":-0.966672,"marketCap":4319289},{"date":"2026-06-26","current":-0.211918,"twenty":-6.088089,"median":-3.102557,"eighty":-0.949468,"marketCap":3958628},{"date":"2026-07-02","current":-0.261949,"twenty":-6.010483,"median":-3.098055,"eighty":-0.939027,"marketCap":4893215},{"date":"2026-07-10","current":-0.248856,"twenty":-6.001989,"median":-3.08079,"eighty":-0.932373,"marketCap":4648635},{"date":"2026-07-17","current":-0.242729,"twenty":-5.989422,"median":-3.058826,"eighty":-0.919078,"marketCap":4534174},{"date":"2026-07-24","current":-0.212583,"twenty":-5.964951,"median":-3.025992,"eighty":-0.912766,"marketCap":3971046},{"date":"2026-07-31","current":-0.207872,"twenty":-5.92149,"median":-2.981001,"eighty":-0.907742,"marketCap":3883041},{"date":"2026-08-07","current":-0.374406,"twenty":-5.913552,"median":-2.958372,"eighty":-0.904979,"marketCap":6791356},{"date":"2026-08-14","current":-0.422125,"twenty":-5.903382,"median":-2.937355,"eighty":-0.902462,"marketCap":7656921},{"date":"2026-08-21","current":-0.473514,"twenty":-5.885273,"median":-2.907657,"eighty":-0.890492,"marketCap":8589068}],"updateTime":1787444292593},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645541558","title":"FibroBiologics shareholders approve 2026 equity incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645541558","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645541558?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:19","pubTimestamp":1782249564,"startTime":"0","endTime":"0","summary":"FibroBiologics held its annual shareholder meeting on June 22, 2026.Shareholders backed the 2026 Equity and Incentive Compensation Plan, replacing the 2022 Stock Plan; the plan became effective June 22, 2026.The plan authorizes 2,061,968 shares for awards, including 2 million newly approved shares, subject to plan terms and adjustments.Shareholders approved issuance of shares tied to outstanding common warrants under the March 31, 2026 Securities Purchase Agreements and the H.C. Wainwright engagement letter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL99cD2z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645902267","title":"Fibrobiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645902267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645902267?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U067:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645229870","title":"FibroBiologics gets USPTO notice of allowance for topical fibroblast spheroid wound-healing patent application","url":"https://stock-news.laohu8.com/highlight/detail?id=2645229870","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645229870?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131456,"startTime":"0","endTime":"0","summary":"FibroBiologics received a USPTO notice of allowance for a U.S. patent application covering topical 3D fibroblast-spheroid therapy for wound healing.The application includes 19 allowed claims for treating wounds using spheroid fibroblasts, alone or with fibroblast-derived materials.Claims cover chronic wounds, including diabetic patients, aligning with lead program CYWC628 in a Phase 1/2 diabetic foot ulcer trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLBRK39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","FBLG","IE00BN0W2W23.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","BK4588","LU2210149790.SGD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645410022","title":"FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645410022","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645410022?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:30","pubTimestamp":1782131400,"startTime":"0","endTime":"0","summary":"Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcersHOUSTON, June  22, 2026  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315281/0/en/FibroBiologics-Receives-Notice-of-Allowance-for-U-S-Patent-Covering-Topical-Fibroblast-Spheroid-Therapy-for-Wound-Healing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","FBLG","BK4585","BK4139","BK4544","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757722","title":"FibroBiologics doses first patients in CYWC628 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757722","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757722?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:58","pubTimestamp":1781614732,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) announced that the first patients have been dosed in the company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-doses-first-patients-in-cywc628-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-doses-first-patients-in-cywc628-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217752","title":"FibroBiologics doses first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217752?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:32","pubTimestamp":1781613150,"startTime":"0","endTime":"0","summary":"FibroBiologics began dosing the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers in early June 2026.No clinical results have been presented; trial readouts are expected in the future.The study is designed to assess initial safety and early signs of benefit in chronic wound healing.Manufacturing scale-up advanced in parallel, with drug product from a second GMP run cleared for shipment to Australia in mid-June 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL1pBTxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","FBLG","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","BK4139","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643752443","title":"Fibrobiologics Inc:  Continues to Advance Manufacturing of Cywc628 to Support Ongoing Trial Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2643752443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643752443?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:30","pubTimestamp":1781613001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA1YYPCL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643752235","title":"Fibrobiologics - to Ship Second Gmp Run of Cywc628 to Australia Week of June 15, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643752235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643752235?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:30","pubTimestamp":1781613001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA1YYPCL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643752148","title":"Fibrobiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of Cywc628 for the Treatment of Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2643752148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643752148?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:30","pubTimestamp":1781613001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA1YYPCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906564","title":"Fibrobiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating Cywc628 for the Treatment of Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906564?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:00","pubTimestamp":1780484401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUABQRCV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640094129","title":"FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2640094129","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640094129?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:00","pubTimestamp":1780484400,"startTime":"0","endTime":"0","summary":"HOUSTON, June  03, 2026  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the dev","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305903/0/en/FibroBiologics-Announces-First-Patients-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CYWC628-for-the-Treatment-of-Diabetic-Foot-Ulcers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637117263","title":"FibroBiologics presents CYPS317 preclinical psoriasis data showing durable immunomodulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2637117263","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637117263?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:31","pubTimestamp":1779453065,"startTime":"0","endTime":"0","summary":"FibroBiologics disclosed preclinical results for its CYPS317 psoriasis program that were presented at the Society for Investigative Dermatology 2026 Annual Meeting held May 13-15, 2026.In mouse studies, a fibroblast spheroid formulation reduced psoriasis-like disease activity while avoiding systemic immune activation seen with single-cell delivery.In a chronic-relapsing model, booster dosing helped sustain the treatment effect, supporting a repeat-dosing approach for longer-term disease control.The data position CYPS317 as a potential differentiated, systemically administered cell therapy strategy for psoriasis, though it remains at the preclinical stage.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL2y721W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","SG9999014005.SGD","LU0314104364.USD","FBLG","SG9999014013.SGD","BK4588","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637311246","title":"Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637311246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637311246?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:30","pubTimestamp":1779453000,"startTime":"0","endTime":"0","summary":"HOUSTON, May 22, 2026  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,  today announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. A link to the poster can be found here.Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17 axis playing a central role in sustaining disease activity. In an imiquimod-induced psoriasis mouse model, both HDF spheroids and single-cell HDF preparations reduced disease severity; however, spheroids provided a more favorable systemic safety profile by avoiding the innate immune activation observed with single-cell delivery, an important distinction for a cell-based therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075854","title":"Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075854?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:32","pubTimestamp":1779107558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075591","title":"FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075591","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075591?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:30","pubTimestamp":1779107400,"startTime":"0","endTime":"0","summary":"HOUSTON, May  18, 2026  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (\"FibroBiologics\"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296634/0/en/FibroBiologics-Files-Patent-Application-for-Oral-Administration-of-Fibroblast-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634238986","title":"FibroBiologics expands fibroblast-based platform to target Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634238986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634238986?lang=en_us&edition=fundamental","pubTime":"2026-05-11 22:42","pubTimestamp":1778510579,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-expands-fibroblast-based-platform-to-target-hantavirus-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-expands-fibroblast-based-platform-to-target-hantavirus-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634924282","title":"Fibrobiologics Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634924282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634924282?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:32","pubTimestamp":1778506370,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634528195","title":"Fibrobiologics Shares NOW Down 15% Premarket at 99 Cents","url":"https://stock-news.laohu8.com/highlight/detail?id=2634528195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634528195?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:45","pubTimestamp":1778503545,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4N41O0ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634289722","title":"FibroBiologics expands fibroblast platform to target Hantavirus pulmonary syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289722?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:31","pubTimestamp":1778502684,"startTime":"0","endTime":"0","summary":"FibroBiologics expanded fibroblast-based platform to target Hantavirus pulmonary syndrome, aiming to translate earlier ARDS work into a new development program.Evaluation underway in Hantavirus disease models, focusing on cytokine modulation and reduced endothelial permeability.Exploratory talks planned with regulatory authorities to define a development pathway toward clinical testing in HPS patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8Dvq0s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","BK4139","SG9999014005.SGD","NDAQ","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","FBLG","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634289786","title":"Fibrobiologics Advancing Development of a Fibroblast Treatment for Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289786?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502621,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":136,"code":"91000000","status":"200"}]}}